AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Zinc Oxide Nanoparticles Demonstrating Directed Cytotoxicity to Leukemia

Technology Benefits

ZnO-NPs exhibit a strong preferential ability to kill cancerous cells compared to healthy tissues. Key research findings show that ZnO-NPs induce toxicity in a cell-specific and proliferation-dependent manner, with rapidly dividing cells being the most susceptible and quiescent cells being the least sensitive. ZnO-NPs have the potential to be delivered directly to cancerous cells through the coupling to targeting ligands specific for cancer cell markers.

Detailed Technology Description

This technology is in early stage development. The nanoparticles cytotoxicity characteristics have been tested in vitro on multiple cell lines. Further development of this technology at Boise State is proceeding through testing of ZnO-NPs cytotoxic characteristics on other cancers cell lines. Attempts at improving their selective cytotoxicity are being made through modifications effecting reactive oxide formation and coupling with tumor-targeting ligands (monoclonal antibodies, peptides, and small molecules). Also, in vivo efficacy and safety studies are planned for the near future.

Supplementary Information

Inventor: Punnoose, Alex | Kongara, Madhusudan R. | Wingett, Denise
Priority Number: US8187638B2
IPC Current: A61K000914 | A61K003308 | A61K003330
US Class: 424489 | 42400133 | 42400161 | 4241551 | 424490 | 424641 | 514494
Assignee Applicant: Boise State University,Boise
Title: Preferential killing of cancer cells and activated human T cells using ZnO nanoparticles
Usefulness: Preferential killing of cancer cells and activated human T cells using ZnO nanoparticles
Summary: The methods are useful for preferentially killing cancer cells over normal cells and for preferentially killing activated T cells over unactivated T cells. Specifically, the methods are used for treating cancer and autoimmune diseases (all claimed). The nanoparticles are particularly used for inducing apoptosis in reactive oxygen species (ROS)-generating cancerous T cells.
Novelty: Preferentially killing cancer cells relative to normal cells comprises treating the cells with zinc oxide nanoparticles

Industry

Disease Diagnostic/Treatment

Sub Group

Cancer/Tumor

Country/Region

USA

For more information, please click Here